[Treatment of the porphyrias].
D000227:Adenine Nucleotides / Q000627:therapeutic use; D001463:Barbiturates / Q000009:adverse effects; D002374:Catalase / Q000627:therapeutic use; D002400:Cathartics / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D003248:Constipation / Q000209:etiology; D004035:Diet Therapy; D004232:Diuretics / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007855:Lead Poisoning; D009422:Nervous System Diseases / Q000209:etiology; D011164:Porphyrias / Q000139:chemically induced / Q000150:complications / Q000209:etiology / Q000628:therapy*; D011736:Pyridoxine / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects; D014803:Vitamin B Complex / Q000627:therapeutic use
D000227:Adenine Nucleotides; D001463:Barbiturates; D002400:Cathartics; D002756:Cholagogues and Choleretics; D004232:Diuretics; D006634:Histamine H1 Antagonists; D013449:Sulfonamides; D014803:Vitamin B Complex; D002374:Catalase; D011736:Pyridoxine; D002746:Chlorpromazine
Die Behandlung der Porphyrien.